dabigatran etexilate + clopidogrel + ticagrelor

This is a **combination therapy** using three agents: dabigatran etexilate (a direct oral anticoagulant, DOAC), clopidogrel (a thienopyridine-class antiplatelet), and ticagrelor (a cyclopentyltriazolopyrimidine-class antiplatelet). Dabigatran is a reversible direct thrombin inhibitor, reducing thrombus formation by blocking the conversion of fibrinogen to fibrin and inhibiting thrombin-mediated platelet aggregation. Clopidogrel and ticagrelor are antiplatelet agents acting as antagonists at the adenosine diphosphate (ADP) P2Y12 receptor on platelets, preventing ADP-mediated platelet activation and aggregation. This combination aims to manage thrombotic risk in situations like atrial fibrillation with recent percutaneous coronary intervention (PCI) or acute coronary syndromes at high ischemic and thromboembolic risk. Combination regimens like these increase antithrombotic efficacy but also carry significantly increased bleeding risk, and are under active clinical investigation[2][3][5].

Brand names

Pradaxa

Other names

dabigatran etexilate + clopidogrel + ticagrelor